Ann Arbor Stage IV Grade 3 Follicular Lymphoma

6 clinical trials · Condition

Record	Firm	Date
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800)	M.D. Anderson Cancer Center	2021-10-13
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma (NCT04404088)	M.D. Anderson Cancer Center	2020-07-16
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (NCT01829568)	National Cancer Institute (NCI)	2013-06-26
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (NCT01286272)	National Cancer Institute (NCI)	2011-04-28
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (NCT01193842)	National Cancer Institute (NCI)	2010-10-06
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma (NCT01145495)	National Cancer Institute (NCI)	2010-06-15

Every clearance here is in the API, with alerts when new ones post.